Euronext's gene therapy debut

How scarcity value helped gene therapy play GenSight go public on Euronext

GenSight Biologics S.A. (Euronext:SIGHT) got out on Euronext thanks in part to investors wanting to own the first European-listed gene therapy company. But it might have to wait for a late 2017 data event before it is valued in line with its closest U.S. comparator.

Last week GenSight raised €40 million ($44.1 million) in an

Read the full 557 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE